Home Finance THERADIAG Posts 2021 Revenue of €11.1 Million, up 7% – Yahoo Finance

THERADIAG Posts 2021 Revenue of €11.1 Million, up 7% – Yahoo Finance

0
THERADIAG Posts 2021 Revenue of €11.1 Million, up 7% – Yahoo Finance

Excellent performance for Theranostics sales, up 13%
Further expansion in activity in the United States, with growth of 17%
Growth in the Company’s historical IVD activity
Cash position at December 31, 2021: €7.1 million
CROISSY-BEAUBOURG, France, January 31, 2022–(BUSINESS WIRE)–Regulatory News:
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and Theranostics, today reported its 2021 annual revenue and its cash position at December 31, 2021.
Bertrand de Castelnau, CEO of Theradiag, commented: "Within a health and economic context that remained hostile, in 2021 Theradiag was able to continue improving its performance indicators. The solid growth in our revenue objectifies our successful strategic refocus on our Theranostics business and the internationalization of our activities in our key geographies. Henceforth, thanks to the funds raised at the end of last year, we will concentrate on the deployment of our strategic plan that will lead to an acceleration in our growth while maintaining strict control over our costs and healthy management of our cash. Our ambition is to strengthen our global leadership position on the biotherapy monitoring market and expand our primary purpose, which is to accompany the therapy of an ever-growing number of patients around the world".
"2021 again demonstrated the resistance of Theradiag’s business model in a delicate public health context. Now having the means to achieve our ambitions, in 2022 Theradiag will be able to begin a new chapter in its history by fully benefiting from its technological lead on the very high potential biotherapy monitoring market", added Pierre Morgon, Chairman of Theradiag’s Board of Directors.
2021 revenue of €11.1 million, up 6.8%
In thousands of euros
FY 2021
FY 2020
Change
Revenue*
11,125
10,413
+6.8%
of which: Theranostics
5,771
5,120
+12.7%
of which: IVD
5,354
5,293
+1.2%
*Figures currently being audited
Over the year to December 31, 2021, Theradiag recorded revenue of €11.1 million, versus €10.1 million in 2020, giving growth of 6.8 % in line with the strategic priorities defined by the Company prior to the Rights Issue implemented at the end of October.
On the strength of the 19 i-Track10 or equivalent analyzers installed and active around the world, Theranostics activity recorded another excellent performance with growth of 12.7% in 2021, and now accounts for 52% of Theradiag’s business.
In Vitro Diagnostics (IVD) activity recorded a slight increase of 1.2% in revenue to €5.3 million. It should be noted that in 2020, Theradiag generated sales associated with the fight against Covid of approximately €900 thousand. In 2021, this activity was marginal.
Globally, Theradiag recorded excellent performances in terms of exports and in the United States with growth of 25.9% and 17.0% respectively reflecting the clear success of its overseas partnerships, such as the one with Veracyte for the marketing of its tests in the United States. In France, activity was down by 5.9%. This slight decrease can be explained by the market’s advanced level of maturity and the negative base effect associated with Covid Ag sales in 2020.
Comfortable cash position with the financing horizon assured until end-2026
At December 31, 2021, Theradiag had a net cash position of €7.1 million, compared to €1.4 million at June 30, 2021; for the last year or so, the Company has been able to stabilize its cash position at around €2 million, excluding capital increase. Henceforth, following the Rights Issue carried out in October 2021, the Company has a financing horizon through to 2026 and thus has medium-term financial autonomy. These additional resources will allow Theradiag to implement its strategic plan whose key routes are to:
– Secure the quality and commercial supply of antibodies via the Humabdiag project developed thanks to the recent partnership with the University of Tours;
– Accelerate the internationalization of existing activities in the world’s main healthcare countries, and in particular accelerate sales in the United States;
– Develop a technological solution to ensure Near Patient Testing;
– Invest in new therapeutic fields with substantial demand and strong growth;
– Reposition and revive FIDIS technology, notably in the United States, as well as the activity covering serums used in quality control.
Reminder of the Company’s 2021 highlights
– CE marking for the new TRACKER® range i-Tracker® test kits: Vedolizumab and Ustekinumab kits on originator and biosimilar molecules;
– Signing of a contract to supply quality control reagents to Orgentec, a specialist in in vitro diagnostics, notably in autoimmunity and infectious diseases;
– Participation in Humabdiag, a large-scale research project undertake with the University of Tours and the University Hospital of Tours targeting the bioproduction of monoclonal antibodies notably for Theradiag and the entire biotherapy market;
– €5.33 million Rights Issue;
– Launch of four new i-Tracker® kits and validation of a new parameter in the United States: Golimumab and Rituximab kits.
Financial calendar:
2021 annual results, Monday March 21, 2022
Annual General Meeting, Thursday May 5, 2022
H1 2022 revenue, Monday July 18, 2022
H1 2022 results, Monday September 19, 2022
About Theradiag
Theradiag is the market leader in biotherapy monitoring. Capitalizing on its expertise in the diagnostics market, the Company has been developing, manufacturing and marketing innovative in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered "theranostics" testing (combining therapy with diagnosis), which measures the efficacy of biotherapy in the treatment of chronic inflammatory diseases. Going beyond mere diagnosis, Theranostics aims to help clinicians set up "customized treatment" for each patient. This method favors the individualization of treatment, evaluation of its efficacy and the prevention of drug resistance. In response to this challenge, Theradiag develops and markets the CE-marked TRACKER® range, a comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has operations in over 70 countries and employs over 60 people. In 2021, the Company posted revenue of €11.1 million. The Theradiag share is listed on Euronext Growth Paris (ISIN: FR0004197747) and is eligible for the French PEA-PME personal equity plan.
For more information about Theradiag, please visit our website: https://www.theradiag.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220130005004/en/
Contacts
Theradiag
Bertrand de Castelnau
CEO/Managing Director
Tel.: +33 (0)1 64 62 10 12
contact@theradiag.com
NewCap
Financial Communications & Investor Relations
Pierre Laurent
Quentin Massé
Tel.: +33 (0)1 44 71 94 94
theradiag@newcap.eu
NewCap
Media Relations
Nicolas Mérigeau
Tel.: +33 (0)1 44 71 94 98
nmerigeau@newcap.fr
The share prices of Lemonade (NYSE: LMND), Upstart Holdings (NASDAQ: UPST), and Block (NYSE: SQ) were rising today as investors appeared to be moving back toward tech stocks, after a major sell-off in the sector earlier this month. Shares of Lemonade were up by 9.7%, Upstart had gained 12.7%, and Block was up by 8.2% as of 11:48 a.m. ET. There wasn't any company-specific news that was driving the share prices of these tech companies higher today.
The stock of Tesla (NASDAQ: TSLA) raced out of the gate Monday morning after the world's most famous electric vehicle (EV) stock won an endorsement from Barron's magazine over the weekend, followed by a second endorsement from Credit Suisse this morning. As of 11 a.m. ET on Monday, Tesla stock was up 9.1%. On Saturday, Barron's called Tesla stock a better buy than either General Motors (NYSE: GM) or Ford (NYSE: F).
Shares of Nvidia (NASDAQ: NVDA) jumped out of the gate Monday and were up 3.5% as of 9:55 a.m. ET. The popular semiconductor stock appears to be responding to a positive prognosis for the global semiconductor industry published by the research firm Gartner. As Livemint.com reported this morning, preliminary results from Gartner show that "worldwide semiconductor revenue increased 25.1% in 2021 to total $583.5 billion, crossing the $500 billion threshold for the first time."
Shares of Tesla (NASDAQ: TSLA) rival Rivian Automotive (NASDAQ: RIVN) are tearing up the track Monday, rising a lucky 7.77% as of 11:25 a.m. ET as investors parse an upgrade for Tesla … and wonder what it might mean for Rivian, too. This morning, as you may have heard, Swiss megabank Credit Suisse upgraded shares of Tesla stock to outperform. Credit Suisse had many reasons for why it loves Tesla — fast growth, high profit margins, and the potential to earn as much as 25% more this year than anyone else on Wall Street thinks possible.
Advanced Micro Devices' (NASDAQ: AMD) planned acquisition of Xilinx (NASDAQ: XLNX), originally announced back in October 2020, is finally getting the green light from the last regulatory agency (approval was already granted in the U.S. and Europe). China's State Administration for Market Regulation gave the go-ahead late last week, paving the way for the two companies to merge, which the two semiconductor designers said should be complete by the end of March 2022. China's regulatory division basically stipulated AMD could proceed on the condition that AMD and Xilinx chips will continue to be made available to China as they have been in the past.
Based on the lowest published price target from Wall Street, the following three stocks are expected to plunge between 42% and 92% in 2022. It likely comes as no surprise that electric vehicle (EV) kingpin Tesla Motors (NASDAQ: TSLA) is a highly polarizing stock among Wall Street analysts. While some believe the company could nearly double in value from the $829 a share it closed at on Jan. 27, Gordon Johnson at GLJ Research foresees Tesla falling more than 90%, based on his price target of $67 for the company.
Shareholders of cloud-based lending platform Upstart (NASDAQ: UPST) have had nothing short of a rollercoaster ride over the past six months. Shares of the company essentially quadrupled in under three months, ultimately hitting an intra-day high of $401 in October. While $401 a share was likely too aggressive a valuation in the near-term, this recent sell-off is the perfect opportunity to buy a game-changing fintech stock with a bright future.
It looks like Blackstone Inc. ( NYSE:BX ) is about to go ex-dividend in the next three days. Typically, the ex-dividend…
Oakmark Funds, an investment management firm, published its “Oakmark Global Select Fund” fourth quarter 2021 investor letter – a copy of which can be seen here. A return of 2.3% was reported by the fund in the fourth quarter of 2021, underperforming the MSCI World Index, which returned 7.8% for the same period. The Fund […]
The market has been indiscriminately punishing tech stocks over the last two months, which has created some attractive entry points for investors. Three stocks that can be picked up at rock-bottom valuations now are Shopify (NYSE: SHOP), CrowdStrike (NASDAQ: CRWD), and MercadoLibre (NASDAQ: MELI). Fortunately, Shopify provides the tools that companies need to rapidly and easily develop an online presence.
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be…
The Nasdaq is bouncing but remains on shaky footing as investors wait to see if the correction is over or will worsen.
The metaverse is one of the hottest trends in technology right now, and it has Wall Street excited — which isn't surprising, as major tech names such as Meta Platforms, Nvidia, Intel (NASDAQ: INTC), Microsoft, and many others are invested in this concept. Goldman Sachs analysts say they think that the metaverse is the next paradigm shift in the way people use the internet. As a result, there are several investment opportunities for investors looking to benefit from the growth of the metaverse.
In this article, we discuss the best monthly dividend stocks to buy for 2022. You can skip our detailed analysis of dividend stocks, and go directly to read 5 Best Monthly Dividend Stocks to Buy for 2022. The importance of dividend-paying stocks cannot be emphasized more in times of financial volatility. During the pandemic in […]
China EV sales boomed in 2021. They are likely to be lower in January after a subsidy cut, but Nio stock rallied Monday.
If bond yields keep rising, tech could keep falling. The Swiss bank advises investors to be strategic about what to buy to take advantage.
Giverny Capital, an asset management firm, published its fourth-quarter 2021 investor letter – a copy of which can be downloaded here. A quarterly net return of 10.73% was delivered by the fund for the fourth quarter of 2021, slightly below its benchmark, the S&P 500 Index, which delivered an 11.03% gain for the same period. […]
It is hard to get excited after looking at Fulgent Genetics' (NASDAQ:FLGT) recent performance, when its stock has…
Is it time to wade in? Yes, if you're confident one thing won't happen, say strategists at Goldman Sachs.
Investors in Roblox (NYSE: RBLX) have had a bumpy ride lately. While existing investors might be upset with the recent share price correction, those who have missed the boat earlier have another opportunity to buy Roblox stock on the cheap. There are many reasons investors might find Roblox a compelling investment opportunity.

source

LEAVE A REPLY

Please enter your comment!
Please enter your name here